Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Based on: 10-Q (reporting date: 2026-09-25), 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
An analysis of the valuation multiples reveals a distinct cyclical pattern characterized by a significant expansion in multiples during 2023 and 2024, followed by a period of relative moderation and stabilization through 2026. The overall trend indicates a period of heightened market optimism peaking in late 2024, specifically regarding earnings and operating profit multiples.
- Price to Earnings (P/E) and Price to Operating Profit (P/OP)
- Both metrics exhibit a high degree of correlation, moving in tandem throughout the observed period. A contraction phase occurred between April 2022 and September 2023, with the P/E ratio reaching a low of 24.76. This was followed by a rapid expansion, peaking in September 2024 at 48.49 for P/E and 39.52 for P/OP. Subsequent quarters show a normalization trend, with the P/E ratio stabilizing between 31.43 and 44.52 during 2025 and 2026.
- Price to Sales (P/S)
- The P/S ratio followed a similar trajectory to earnings multiples, though with less volatility. After maintaining a range between 5.63 and 6.77 through 2023, the ratio peaked at 8.10 in June 2024. A general downward trend was observed from mid-2024 through June 2026, where the ratio hit a period low of 5.01, before recovering to 6.42 by September 2026.
- Price to Book Value (P/BV)
- Unlike the other valuation metrics, the P/BV ratio demonstrates a consistent long-term downward trend. Starting at 4.36 in early 2022, the multiple declined steadily, reaching a low of 2.39 in June 2026. This sustained contraction suggests that the market valuation of the entity has decreased relative to its book value, even during periods when earnings and sales multiples were expanding.
The divergence between the peaking earnings multiples in 2024 and the steadily declining book value multiple suggests a shift in valuation drivers. While the market remained willing to pay a premium for earnings power and revenue growth, the premium attributed to tangible assets experienced a continuous compression over the entire period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Earnings (P/E)
| Sep 25, 2026 | Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 703,530,815 | 702,986,054 | 707,770,627 | 707,139,356 | 706,349,563 | 716,051,590 | 715,669,594 | 714,709,852 | 722,275,141 | 722,213,081 | 740,686,541 | 739,701,725 | 738,927,107 | 738,352,114 | 737,898,789 | 728,576,886 | 727,962,702 | 727,445,355 | 727,076,766 | ||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Net earnings attributable to common stockholders (in millions) | 1,235) | 870) | 1,029) | 1,197) | 908) | 555) | 954) | 1,086) | 818) | 907) | 1,088) | 1,079) | 1,129) | 1,106) | 1,429) | 2,210) | 1,551) | 1,658) | 1,684) | ||||||
| Earnings per share (EPS)2 | 6.16 | 5.70 | 5.21 | 5.11 | 4.96 | 4.77 | 5.26 | 5.46 | 5.39 | 5.82 | 5.94 | 6.41 | 7.95 | 8.53 | 9.28 | 9.75 | 9.12 | 8.53 | 8.65 | ||||||
| Share price1, 3 | 233.86 | 179.01 | 194.54 | 209.19 | 220.77 | 189.91 | 192.07 | 207.95 | 261.28 | 264.18 | 253.11 | 250.65 | 196.84 | 255.70 | 231.99 | 250.11 | 243.08 | 279.23 | 278.24 | ||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/E ratio4 | 37.99 | 31.43 | 37.32 | 40.93 | 44.52 | 39.84 | 36.51 | 38.12 | 48.49 | 45.39 | 42.59 | 39.09 | 24.76 | 29.99 | 25.00 | 25.65 | 26.65 | 32.73 | 32.15 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| P/E Ratio, Competitors5 | |||||||||||||||||||||||||
| AbbVie Inc. | — | 68.64 | 97.96 | 94.06 | 159.78 | 92.57 | 77.73 | 79.59 | 69.16 | 62.04 | 48.26 | 63.84 | 38.27 | 30.55 | 34.43 | 22.62 | 19.16 | 19.44 | 21.64 | ||||||
| Amgen Inc. | — | 25.22 | 22.82 | 25.81 | 24.59 | 23.15 | 25.49 | 38.24 | 40.68 | 53.65 | 44.38 | 23.14 | 18.09 | 16.31 | 16.18 | 19.56 | 21.00 | 20.03 | 22.23 | ||||||
| Bristol-Myers Squibb Co. | — | 14.27 | 17.01 | 17.30 | 15.38 | 17.46 | 18.29 | — | — | — | — | 12.27 | 13.01 | 15.93 | 19.43 | 23.97 | 23.71 | 24.14 | 25.64 | ||||||
| Eli Lilly & Co. | — | 41.23 | 34.82 | 47.45 | 43.36 | 43.95 | 67.76 | 77.63 | 96.05 | 109.42 | 120.94 | 135.24 | 110.43 | 76.21 | 65.16 | 50.08 | 55.53 | 51.05 | 45.29 | ||||||
| Gilead Sciences Inc. | — | — | 18.06 | 21.54 | 18.18 | 21.68 | 20.62 | 296.57 | 925.87 | 89.29 | 166.76 | 16.17 | 17.10 | 17.88 | 17.75 | 22.68 | 29.30 | 18.66 | 17.25 | ||||||
| Johnson & Johnson | 38.56 | 29.70 | 25.87 | 21.66 | 18.51 | 18.02 | 17.14 | 26.92 | 27.19 | 10.11 | 9.46 | 10.73 | 10.12 | 33.35 | 33.43 | 22.97 | 23.52 | 24.98 | 23.95 | ||||||
| Merck & Co. Inc. | — | 99.98 | 31.27 | 16.79 | 11.00 | 12.30 | 11.98 | 13.49 | 20.98 | 20.73 | 140.05 | 893.99 | 56.85 | 86.53 | 22.92 | 19.21 | 16.41 | 13.36 | 15.70 | ||||||
| Pfizer Inc. | — | 33.42 | 20.12 | 19.83 | 14.06 | 13.09 | 17.22 | 18.42 | 37.00 | — | — | 73.42 | 16.60 | 9.42 | 7.44 | 7.58 | 8.81 | 9.56 | 11.11 | ||||||
| Regeneron Pharmaceuticals Inc. | — | 17.56 | 16.27 | 18.19 | 15.03 | 13.29 | 13.65 | 17.76 | 19.79 | 27.88 | 26.78 | 25.99 | 22.35 | 19.48 | 19.77 | 19.68 | 14.98 | 11.67 | 9.15 | ||||||
| Thermo Fisher Scientific Inc. | — | 30.48 | 25.46 | 28.82 | 32.45 | 26.56 | 24.55 | 32.03 | 34.78 | 37.81 | 36.21 | 35.65 | 29.57 | 37.01 | 34.99 | 30.55 | 27.64 | 31.09 | 28.15 | ||||||
| Vertex Pharmaceuticals Inc. | — | 27.54 | 24.83 | 31.58 | 29.11 | 26.43 | — | — | — | — | 26.34 | 30.42 | 28.09 | 27.49 | 27.34 | 23.02 | 24.62 | 23.12 | 26.50 | ||||||
Based on: 10-Q (reporting date: 2026-09-25), 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
EPS
= (Net earnings attributable to common stockholdersQ3 2026
+ Net earnings attributable to common stockholdersQ2 2026
+ Net earnings attributable to common stockholdersQ1 2026
+ Net earnings attributable to common stockholdersQ4 2025)
÷ No. shares of common stock outstanding
= (1,235,000,000 + 870,000,000 + 1,029,000,000 + 1,197,000,000)
÷ 703,530,815 = 6.16
3 Closing price as at the filing date of Danaher Corp. Quarterly or Annual Report.
4 Q3 2026 Calculation
P/E ratio = Share price ÷ EPS
= 233.86 ÷ 6.16 = 37.99
5 Click competitor name to see calculations.
The valuation metrics for the period between April 2022 and September 2026 exhibit a notable divergence between earnings performance and market valuation. While earnings per share experienced a prolonged decline before recovering in 2026, the price-to-earnings ratio expanded significantly, indicating a shift in market sentiment or a premium placed on future growth expectations despite contracting current earnings.
- Earnings Per Share (EPS) Trends
- A consistent downward trajectory in earnings per share is observed starting from a peak of 9.75 US$ in December 2022. This decline persisted through much of 2023 and 2024, reaching a trough of 4.77 US$ in June 2025. A recovery phase began in early 2026, with EPS climbing steadily to reach 6.16 US$ by September 2026, although this remains below the levels recorded in 2022.
- Share Price Volatility
- The share price demonstrated significant volatility, characterized by an initial decline from 2022 highs of approximately 279 US$ to a low of 196.84 US$ in September 2023. Subsequent periods showed erratic movement, with a recovery toward 264 US$ in June 2024, followed by another decline to 179.01 US$ in June 2026, before ending the period at 233.86 US$.
- Price-to-Earnings (P/E) Ratio Expansion
- The P/E ratio underwent a substantial expansion during the period when earnings were contracting. From a low of 24.76 in September 2023, the ratio surged to a peak of 48.49 by September 2024. This expansion suggests that the market maintained or increased its valuation of the company despite the reduction in EPS. Following this peak, the ratio fluctuated between 31.43 and 44.52, eventually settling at 37.99 in September 2026.
- Correlation Analysis
- An inverse relationship is observable between EPS and the P/E ratio from 2023 through 2024. The sharp increase in the P/E ratio during this window confirms that the share price did not decline in proportion to the falling earnings, leading to a higher valuation multiple. The stabilization of the P/E ratio in 2026 coincides with the return to earnings growth, suggesting a transition toward a more balanced valuation basis.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Operating Profit (P/OP)
| Sep 25, 2026 | Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 703,530,815 | 702,986,054 | 707,770,627 | 707,139,356 | 706,349,563 | 716,051,590 | 715,669,594 | 714,709,852 | 722,275,141 | 722,213,081 | 740,686,541 | 739,701,725 | 738,927,107 | 738,352,114 | 737,898,789 | 728,576,886 | 727,962,702 | 727,445,355 | 727,076,766 | ||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Operating profit (in millions) | 1,245) | 1,127) | 1,344) | 1,502) | 1,154) | 760) | 1,274) | 1,425) | 958) | 1,168) | 1,312) | 1,337) | 1,185) | 1,163) | 1,517) | 2,296) | 2,015) | 2,205) | 2,172) | ||||||
| Operating profit per share2 | 7.42 | 7.29 | 6.73 | 6.63 | 6.53 | 6.17 | 6.74 | 6.80 | 6.61 | 6.93 | 6.75 | 7.03 | 8.34 | 9.47 | 10.89 | 11.92 | 11.74 | 10.78 | 10.51 | ||||||
| Share price1, 3 | 233.86 | 179.01 | 194.54 | 209.19 | 220.77 | 189.91 | 192.07 | 207.95 | 261.28 | 264.18 | 253.11 | 250.65 | 196.84 | 255.70 | 231.99 | 250.11 | 243.08 | 279.23 | 278.24 | ||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/OP ratio4 | 31.53 | 24.54 | 28.93 | 31.54 | 33.80 | 30.79 | 28.49 | 30.56 | 39.52 | 38.14 | 37.52 | 35.64 | 23.61 | 27.01 | 21.31 | 20.97 | 20.71 | 25.91 | 26.48 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | |||||||||||||||||||||||||
| AbbVie Inc. | — | 25.67 | 23.23 | 26.37 | 42.20 | 31.76 | 32.37 | 37.26 | 25.63 | 26.99 | 22.62 | 24.34 | 16.55 | 15.26 | 16.15 | 14.78 | 14.52 | 14.12 | 14.57 | ||||||
| Amgen Inc. | — | 19.30 | 16.84 | 21.92 | 19.86 | 18.71 | 20.31 | 21.55 | 27.68 | 27.12 | 23.97 | 19.69 | 15.45 | 13.71 | 14.25 | 13.40 | 14.89 | 14.08 | 15.88 | ||||||
| Bristol-Myers Squibb Co. | — | 11.30 | 12.42 | 12.20 | 10.25 | 11.07 | 13.65 | — | — | — | — | 13.53 | 14.14 | 16.24 | 17.09 | 18.29 | 17.79 | 18.62 | 20.32 | ||||||
| Eli Lilly & Co. | — | 32.74 | 27.92 | 37.24 | 34.60 | 35.19 | 53.43 | 63.73 | 79.30 | 88.66 | 99.34 | 109.75 | 93.27 | 69.42 | 59.60 | 43.88 | 46.48 | 39.20 | 36.49 | ||||||
| Gilead Sciences Inc. | — | — | 16.05 | 18.29 | 14.06 | 17.00 | 14.96 | 85.65 | 143.05 | 36.80 | 51.26 | 12.05 | 12.16 | 11.57 | 11.21 | 14.21 | 16.27 | 11.02 | 10.78 | ||||||
| Johnson & Johnson | 25.09 | 24.10 | 21.40 | 22.95 | 19.83 | 19.04 | 17.74 | 18.20 | 18.65 | 17.54 | 16.96 | 17.78 | 15.69 | 18.91 | 18.26 | 17.62 | 19.64 | 20.45 | 21.06 | ||||||
| Merck & Co. Inc. | — | 49.74 | 23.37 | 14.44 | 9.67 | 10.57 | 10.37 | 11.60 | 18.67 | 18.41 | 75.94 | 138.56 | 33.75 | 44.67 | 18.53 | 15.55 | 13.85 | 11.72 | 14.29 | ||||||
| Pfizer Inc. | — | 10.48 | 10.37 | 10.82 | 10.07 | 9.49 | 11.27 | 11.92 | 27.24 | — | — | 121.63 | 17.49 | 9.17 | 6.74 | 6.80 | 7.82 | 9.11 | 11.49 | ||||||
| Regeneron Pharmaceuticals Inc. | — | 19.78 | 19.83 | 22.90 | 18.65 | 15.42 | 16.03 | 19.63 | 23.18 | 30.86 | 26.82 | 25.39 | 21.13 | 19.32 | 18.68 | 18.01 | 12.91 | 9.68 | 7.98 | ||||||
| Thermo Fisher Scientific Inc. | — | 26.07 | 22.09 | 24.94 | 28.40 | 23.62 | 21.64 | 27.65 | 29.74 | 32.66 | 31.40 | 31.16 | 25.59 | 31.55 | 29.54 | 25.30 | 21.43 | 23.99 | 21.84 | ||||||
| Vertex Pharmaceuticals Inc. | — | 25.40 | 23.01 | 29.92 | 26.79 | 24.50 | — | — | — | — | 25.25 | 28.74 | 25.14 | 23.33 | 22.03 | 17.75 | 19.41 | 18.11 | 22.13 | ||||||
Based on: 10-Q (reporting date: 2026-09-25), 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
Operating profit per share
= (Operating profitQ3 2026
+ Operating profitQ2 2026
+ Operating profitQ1 2026
+ Operating profitQ4 2025)
÷ No. shares of common stock outstanding
= (1,245,000,000 + 1,127,000,000 + 1,344,000,000 + 1,502,000,000)
÷ 703,530,815 = 7.42
3 Closing price as at the filing date of Danaher Corp. Quarterly or Annual Report.
4 Q3 2026 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 233.86 ÷ 7.42 = 31.53
5 Click competitor name to see calculations.
The financial data for the period between April 2022 and September 2026 reveals a significant divergence between operating performance and market valuation. While operating profit per share experienced a sustained decline for several years, the Price to operating profit (P/OP) ratio expanded significantly, indicating a period of valuation inflation relative to actual earnings before a subsequent correction.
- Operating Profit Trends
- Operating profit per share peaked in December 2022 at 11.92 USD. Following this peak, a consistent downward trend was observed, reaching a minimum of 6.17 USD by June 2025. A moderate recovery occurred in the final quarters of the observed period, with the figure rising to 7.42 USD by September 2026.
- P/OP Ratio Fluctuations
- The P/OP ratio exhibited three distinct phases. From April 2022 to March 2023, the ratio remained relatively stable, fluctuating between 20.71 and 26.48. A period of aggressive expansion followed, with the ratio climbing to a peak of 39.52 in September 2024. In the final phase, from December 2024 through September 2026, the ratio experienced a downward correction and increased volatility, ending at 31.53.
- Share Price Correlation
- The share price demonstrated significant volatility, with a notable dip to 196.84 USD in September 2023. However, the P/OP ratio continued to rise throughout 2024 despite the operating profit remaining suppressed. This suggests that market valuation during 2024 was driven by factors other than immediate operating profitability, as the ratio reached its highest levels while operating profit per share was near its lowest points.
- Valuation Analysis
- The expansion of the P/OP ratio from approximately 21.31 in March 2023 to 39.52 in September 2024 represents a substantial increase in the multiple the market was willing to pay for operating profits. The subsequent decline in the ratio toward 2026 suggests a market realignment, bringing the valuation closer to the fundamental operating performance of the entity.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Sales (P/S)
| Sep 25, 2026 | Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 703,530,815 | 702,986,054 | 707,770,627 | 707,139,356 | 706,349,563 | 716,051,590 | 715,669,594 | 714,709,852 | 722,275,141 | 722,213,081 | 740,686,541 | 739,701,725 | 738,927,107 | 738,352,114 | 737,898,789 | 728,576,886 | 727,962,702 | 727,445,355 | 727,076,766 | ||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Sales (in millions) | 6,554) | 6,265) | 5,951) | 6,838) | 6,053) | 5,936) | 5,741) | 6,538) | 5,798) | 5,743) | 5,796) | 6,405) | 5,624) | 5,912) | 5,949) | 8,369) | 7,663) | 7,751) | 7,688) | ||||||
| Sales per share2 | 36.40 | 35.71 | 35.01 | 34.74 | 34.36 | 33.54 | 33.28 | 33.41 | 32.87 | 32.63 | 32.05 | 32.30 | 34.99 | 37.78 | 40.29 | 43.20 | 42.93 | 42.36 | 41.65 | ||||||
| Share price1, 3 | 233.86 | 179.01 | 194.54 | 209.19 | 220.77 | 189.91 | 192.07 | 207.95 | 261.28 | 264.18 | 253.11 | 250.65 | 196.84 | 255.70 | 231.99 | 250.11 | 243.08 | 279.23 | 278.24 | ||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/S ratio4 | 6.42 | 5.01 | 5.56 | 6.02 | 6.43 | 5.66 | 5.77 | 6.23 | 7.95 | 8.10 | 7.90 | 7.76 | 5.63 | 6.77 | 5.76 | 5.79 | 5.66 | 6.59 | 6.68 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| P/S Ratio, Competitors5 | |||||||||||||||||||||||||
| AbbVie Inc. | — | 6.73 | 5.67 | 6.50 | 6.40 | 5.97 | 5.68 | 6.04 | 6.38 | 6.02 | 5.32 | 5.72 | 4.52 | 4.74 | 4.60 | 4.61 | 4.44 | 4.28 | 4.76 | ||||||
| Amgen Inc. | — | 6.08 | 5.02 | 5.66 | 4.99 | 4.57 | 4.61 | 4.88 | 5.53 | 5.68 | 5.93 | 5.78 | 5.34 | 5.14 | 5.14 | 5.17 | 5.85 | 5.35 | 5.21 | ||||||
| Bristol-Myers Squibb Co. | — | 2.69 | 2.55 | 2.53 | 1.93 | 1.85 | 2.08 | 2.36 | 2.38 | 2.20 | 1.99 | 2.19 | 2.40 | 2.81 | 3.10 | 3.29 | 3.39 | 3.39 | 3.41 | ||||||
| Eli Lilly & Co. | — | 13.82 | 12.18 | 15.03 | 13.44 | 11.39 | 15.36 | 18.25 | 19.67 | 20.64 | 20.66 | 20.77 | 17.18 | 16.78 | 13.38 | 10.96 | 11.46 | 9.99 | 9.47 | ||||||
| Gilead Sciences Inc. | — | 5.44 | 5.69 | 6.34 | 5.16 | 4.76 | 4.31 | 4.98 | 4.18 | 3.41 | 2.97 | 3.40 | 3.69 | 3.61 | 3.70 | 3.86 | 3.64 | 2.84 | 2.86 | ||||||
| Johnson & Johnson | 6.25 | 6.38 | 5.65 | 6.16 | 5.04 | 4.51 | 4.19 | 4.26 | 4.55 | 4.44 | 4.25 | 4.43 | 4.01 | 4.84 | 4.60 | 4.34 | 4.69 | 4.80 | 5.00 | ||||||
| Merck & Co. Inc. | — | 4.77 | 4.25 | 4.71 | 3.26 | 3.17 | 3.27 | 3.60 | 4.03 | 4.56 | 5.26 | 5.43 | 4.42 | 4.62 | 5.16 | 4.71 | 4.25 | 3.87 | 4.12 | ||||||
| Pfizer Inc. | — | 2.27 | 2.38 | 2.46 | 2.20 | 2.20 | 2.17 | 2.32 | 2.60 | 3.00 | 2.86 | 2.61 | 2.51 | 2.58 | 2.32 | 2.37 | 2.63 | 2.77 | 3.00 | ||||||
| Regeneron Pharmaceuticals Inc. | — | 4.89 | 4.82 | 5.71 | 4.83 | 4.17 | 4.36 | 5.52 | 6.65 | 8.93 | 7.89 | 7.84 | 6.81 | 6.61 | 6.69 | 7.01 | 5.87 | 4.66 | 4.40 | ||||||
| Thermo Fisher Scientific Inc. | — | 4.58 | 3.86 | 4.34 | 4.87 | 4.05 | 3.73 | 4.73 | 5.04 | 5.55 | 5.14 | 4.99 | 4.05 | 4.87 | 4.81 | 4.73 | 4.40 | 5.40 | 5.20 | ||||||
| Vertex Pharmaceuticals Inc. | — | 9.64 | 8.82 | 10.40 | 9.13 | 8.42 | 10.41 | 10.78 | 12.12 | 12.35 | 10.39 | 11.16 | 10.10 | 9.73 | 9.68 | 8.56 | 9.26 | 8.85 | 8.17 | ||||||
Based on: 10-Q (reporting date: 2026-09-25), 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
Sales per share
= (SalesQ3 2026
+ SalesQ2 2026
+ SalesQ1 2026
+ SalesQ4 2025)
÷ No. shares of common stock outstanding
= (6,554,000,000 + 6,265,000,000 + 5,951,000,000 + 6,838,000,000)
÷ 703,530,815 = 36.40
3 Closing price as at the filing date of Danaher Corp. Quarterly or Annual Report.
4 Q3 2026 Calculation
P/S ratio = Share price ÷ Sales per share
= 233.86 ÷ 36.40 = 6.42
5 Click competitor name to see calculations.
The valuation of the common stock exhibits significant volatility in the Price to Sales (P/S) ratio between April 2022 and September 2026. The ratio fluctuated from a low of 5.01 to a high of 8.10, indicating shifting market sentiment regarding the company's revenue generation and growth prospects over the analyzed period.
- Price to Sales (P/S) Ratio Trends
- The P/S ratio experienced three distinct phases. An initial period of relative stability occurred between April 2022 and September 2023, with values ranging between 5.63 and 6.77. This was followed by a sharp expansion in valuation, peaking at 8.10 in June 2024. A subsequent contraction phase saw the ratio decline to a period low of 5.01 by June 2026, before recovering to 6.42 in September 2026.
- Revenue Per Share Dynamics
- Sales per share showed a downward trajectory from a peak of 43.20 in December 2022 to a trough of 32.05 in March 2024. Following this decline, a gradual recovery trend is observed, with sales per share steadily increasing to 36.40 by September 2026. The inverse relationship between the sales trough and the P/S peak suggests that the valuation expanded even as revenue per share weakened during the first half of 2024.
- Share Price Correlation
- The share price demonstrated notable volatility, with peaks in June 2023 (255.70) and June 2024 (264.18). The highest P/S ratios were driven primarily by increases in the share price during periods where sales per share remained suppressed. The most significant valuation contraction occurred between June 2024 and June 2026, as the share price trended generally downward from 264.18 to 179.01, outweighing the modest recovery in sales per share and leading to a compression of the valuation multiple.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Book Value (P/BV)
| Sep 25, 2026 | Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 703,530,815 | 702,986,054 | 707,770,627 | 707,139,356 | 706,349,563 | 716,051,590 | 715,669,594 | 714,709,852 | 722,275,141 | 722,213,081 | 740,686,541 | 739,701,725 | 738,927,107 | 738,352,114 | 737,898,789 | 728,576,886 | 727,962,702 | 727,445,355 | 727,076,766 | ||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Total Danaher stockholders’ equity (in millions) | 53,621) | 52,581) | 52,949) | 52,534) | 51,071) | 52,334) | 50,849) | 49,543) | 51,299) | 49,897) | 53,442) | 53,486) | 52,407) | 51,716) | 51,478) | 50,082) | 46,985) | 46,594) | 46,356) | ||||||
| Book value per share (BVPS)2 | 76.22 | 74.80 | 74.81 | 74.29 | 72.30 | 73.09 | 71.05 | 69.32 | 71.02 | 69.09 | 72.15 | 72.31 | 70.92 | 70.04 | 69.76 | 68.74 | 64.54 | 64.05 | 63.76 | ||||||
| Share price1, 3 | 233.86 | 179.01 | 194.54 | 209.19 | 220.77 | 189.91 | 192.07 | 207.95 | 261.28 | 264.18 | 253.11 | 250.65 | 196.84 | 255.70 | 231.99 | 250.11 | 243.08 | 279.23 | 278.24 | ||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/BV ratio4 | 3.07 | 2.39 | 2.60 | 2.82 | 3.05 | 2.60 | 2.70 | 3.00 | 3.68 | 3.82 | 3.51 | 3.47 | 2.78 | 3.65 | 3.33 | 3.64 | 3.77 | 4.36 | 4.36 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | |||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | 229.63 | 102.40 | 58.73 | 48.87 | 36.12 | 29.97 | 20.61 | 20.62 | 19.68 | 15.52 | 16.06 | 16.76 | 16.59 | ||||||
| Amgen Inc. | — | 18.86 | 19.37 | 22.99 | 17.91 | 20.63 | 24.36 | 26.61 | 22.86 | 28.34 | 33.25 | 24.94 | 17.87 | 19.19 | 23.95 | 35.01 | 39.30 | 54.46 | 138.87 | ||||||
| Bristol-Myers Squibb Co. | — | 5.94 | 6.17 | 6.61 | 5.01 | 5.06 | 5.70 | 6.98 | 6.60 | 6.01 | 5.49 | 3.35 | 3.72 | 3.97 | 4.46 | 4.88 | 4.85 | 4.90 | 5.07 | ||||||
| Eli Lilly & Co. | — | 32.51 | 28.21 | 36.91 | 33.55 | 33.19 | 47.74 | 57.93 | 56.45 | 59.24 | 57.94 | 65.80 | 49.10 | 44.75 | 33.11 | 29.36 | 33.27 | 34.00 | 29.75 | ||||||
| Gilead Sciences Inc. | — | 13.72 | 7.08 | 8.07 | 6.85 | 6.96 | 6.42 | 7.36 | 6.36 | 5.15 | 4.61 | 4.01 | 4.50 | 4.63 | 4.72 | 4.90 | 4.63 | 3.82 | 3.91 | ||||||
| Johnson & Johnson | 7.61 | 7.35 | 6.70 | 7.12 | 5.86 | 5.20 | 4.79 | 5.30 | 5.69 | 5.37 | 5.20 | 5.48 | 4.92 | 5.79 | 6.00 | 5.37 | 6.04 | 6.01 | 6.36 | ||||||
| Merck & Co. Inc. | — | 7.57 | 6.09 | 5.82 | 4.04 | 4.12 | 4.32 | 4.99 | 5.73 | 6.53 | 8.00 | 8.68 | 6.35 | 6.96 | 6.38 | 6.07 | 5.63 | 5.12 | 5.44 | ||||||
| Pfizer Inc. | — | 1.70 | 1.67 | 1.78 | 1.49 | 1.59 | 1.50 | 1.68 | 1.70 | 1.92 | 1.74 | 1.75 | 1.80 | 2.04 | 2.14 | 2.48 | 2.83 | 3.21 | 3.37 | ||||||
| Regeneron Pharmaceuticals Inc. | — | 2.40 | 2.29 | 2.62 | 2.22 | 1.98 | 2.09 | 2.67 | 3.14 | 4.27 | 3.83 | 3.96 | 3.58 | 3.49 | 3.52 | 3.77 | 3.75 | 3.21 | 3.65 | ||||||
| Thermo Fisher Scientific Inc. | — | 4.03 | 3.36 | 3.62 | 4.18 | 3.46 | 3.24 | 4.09 | 4.36 | 4.96 | 4.80 | 4.57 | 3.88 | 4.84 | 4.99 | 4.83 | 4.46 | 5.47 | 5.23 | ||||||
| Vertex Pharmaceuticals Inc. | — | 5.99 | 5.56 | 6.69 | 6.18 | 5.60 | 7.01 | 7.24 | 8.24 | 8.64 | 5.71 | 6.26 | 5.90 | 5.98 | 6.18 | 5.50 | 6.18 | 6.19 | 5.95 | ||||||
Based on: 10-Q (reporting date: 2026-09-25), 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
BVPS = Total Danaher stockholders’ equity ÷ No. shares of common stock outstanding
= 53,621,000,000 ÷ 703,530,815 = 76.22
3 Closing price as at the filing date of Danaher Corp. Quarterly or Annual Report.
4 Q3 2026 Calculation
P/BV ratio = Share price ÷ BVPS
= 233.86 ÷ 76.22 = 3.07
5 Click competitor name to see calculations.
The valuation metrics exhibit a general contraction in the price-to-book value (P/BV) multiple over the analyzed period, characterized by a divergence between steady growth in book value and increased volatility in the market price.
- Book Value per Share (BVPS) Trend
- A consistent upward trajectory is observed in the book value per share, which rose from 63.76 US$ in April 2022 to 76.22 US$ by September 2026. This represents a steady accumulation of net assets on a per-share basis, indicating a strengthening of the company's underlying equity position throughout the period.
- Share Price Volatility
- The share price experienced significant fluctuations, peaking at 279.23 US$ in July 2022 before entering a period of instability. Notable troughs occurred in September 2023 (196.84 US$), December 2024 (207.95 US$), and June 2026 (179.01 US$), reflecting market sensitivity and price corrections that occurred independently of the growth in book value.
- Price-to-Book Value (P/BV) Analysis
- The P/BV ratio demonstrates a long-term downward trend, declining from a peak of 4.36 in early 2022 to a period low of 2.39 in June 2026. This compression of the multiple indicates that the market has assigned a lower premium to the company's net assets over time. While the ratio recovered to 3.07 by September 2026, it remained substantially below the 2022 levels.
- Correlation and Valuation Insight
- The decline in the P/BV ratio was primarily driven by share price depreciation rather than a loss of asset value. Because the BVPS grew while the share price generally trended lower or remained volatile, the resulting valuation multiple contracted. This suggests a shift in market sentiment or a re-rating of the company's valuation relative to its accounting equity.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?